James Larner headshot

Jim Larner

Unit: School of Medicine
Department: Department of Radiation Oncology
Office location and address
Emily Couric Clinical Cancer Center
21 Hospital Dr
Charlottesville, Virginia 22903
BS, Premedical Studies, Hampshire College, Amherst, MA
MD, Medicine, University of Virginia
Medical Internship, Albany Medical College, Albany, NY
Resident, Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA
Clinical Research Fellowship, Hematology, Cardeza Foundation for Hematologic Research, Thomas Jefferson University Hospital, Philadelphia, PA
Fellowship, Medical Oncology, Albert Einstein College of Medicine, Bronx, NY

In addition to a leadership role as chair of Radiation Oncology, Larner serves the Cancer Center in a number of critical positions, including co-leader of the Genetics and Epigenetics Program, chair of the Cancer Center Protocol Review and Monitoring Committee, Chair of the School of Medicine Research Advisory Committee. He earned his medical degree at UVA in 1980 and has been here for the last 25 years.

Spending an estimated 60 percent of his time on research and 40 percent in the clinic, Larner is dedicated to both key areas of the Cancer Center. His research interests include DNA damage-sensing pathways, radiation injury, radiosensitizers (drugs that make tumor cells more responsive to radiation therapy), prostate cancer, gliomas (brain tumors) and lung cancer. Larner’s clinical interests include cancer of the brain, central nervous system, thorax and lungs.

When he is not in the lab or clinic, Larner plays racquet sports, restores houses and travels. He claims he spoils his son by allowing him to select where they travel each year. Some of Larner’s favorite destinations include Mauritius, Thailand, Andora, Uruguay and Japan.

The Role of ZEB1 in promoting therapeutic resistance through its interaction with 53BP1
Source: U.S. NIH Cancer Institute
February 01, 2022 – January 31, 2027
MD-RONC-A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies
Source: Merck Sharp & Dohme LLC
December 28, 2016 – June 30, 2022
Promoting the Endogenous Degradation of the AR Via the Proteasome to Eliminate the Receptor from Tumor Cells
Source: The V Foundation for Cancer Research
November 01, 2019 – November 01, 2021
MD-RONC-JML2P Dual Targeting of AR and HIF1a to Promote Radiosensitization of Prostate Cancer
Source: U.S. NIH Cancer Institute
January 01, 2015 – December 31, 2019
Focused Ultrasound Foundation Support Padilla
Source: Focused Ultrasound Foundation
August 07, 2017 – August 06, 2019
MD-RONC A Pilot Study to Assess the Combination of Sterotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systematic T-Cell Responses Against Prostate Cancer
Source: Celldex Therapeutics, Inc.
September 23, 2014 – September 30, 2018
MD-RONC FUSF Support Lafon
Source: Focused Ultrasound Foundation
July 01, 2016 – July 10, 2017
MD-RONC-JML2P Insightec BM018: A Phase IV Post Approval CLinical Study of ExAblate Treatment of Metastatic Bone Tumers for the Palliation of Pain - BM018
Source: InSightec - Image Guided Treatment Ltd.
August 19, 2013 – September 30, 2016
MD-RONC FUSF Support Paeng
Source: Focused Ultrasound Foundation
January 01, 2015 – June 30, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
Director of Focused UltraSound
Source: Focused Ultrasound Foundation
September 01, 2010 – August 31, 2015
MD-ROND-JML2P-Insightec BM019 A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain
Source: InSightec - Image Guided Treatment Ltd.
August 21, 2013 – August 20, 2015
MD-RONC-JML2P-INCDiffusion 100-202 GBM Phase 1/2
Source: Syneos Health, LLC
November 01, 2011 – October 31, 2014
RONC-FUSF Support for Aubry
Source: Focused Ultrasound Foundation
August 01, 2012 – August 19, 2013
MD-RONC Mechanisms of Radiosensitization by 2-Methoxyestradiol in Prostate Cancer Models
Source: U.S. NIH Cancer Institute
May 01, 2008 – February 28, 2013
  • 2015 One of America's Top Cancer Doctors, Newsweek®
  • 2015 Bedside Manner Award, Our Health Magazine; Third place
  • 2012 Best Doctors in America® List